Results of the Combined General Shareholders’ Meeting of August 31, 2020
01/09/2020 – AB Science announces the results of the Combined Shareholders’ Meeting of August 31, 2020
New results published in Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s Disease
08/07/2020 – AB Science announces that new results published in the peer-reviewed Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s Disease
Presentation of the results from AB8939 preclinical program in AML in EHA 2020 Annual Congress
10/06/2020 – AB Science will present results from AB8939 preclinical program in acute myeloid leukemia at the EHA 2020 Annual Congress
Postponement of AB Science Annual General Shareholders’ meeting
22/05/2020 – AB Science announces the postponement of its annual general shareholders’ meeting
Live webcast on masitinib in combination with isoquercetine for the treatment of COVID-19 on Monday May 11, 2020
07/05/2020 – AB Science will host a live webcast on masitinib in combination with isoquercetin for the treatment of COVID-19 on Monday May 11, 2020
Presentation of the results from the Phase 3 AB07015 study in severe asthma at the EAACI 2020 Annual Congress
07/05/2020 – AB Science will present results from its Phase 3 study in severe asthma at the EEACI 2020 Annual Congress
Authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19
06/05/2020 – AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19
Annual financial results as of 31 December, 2019
30/04/2020 – AB Science reports its annual financial results as of 31 December, 2019
Letter to our stakeholders on COVID-19 pandemic impact on AB Science studies
03/04/2020 – A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies
FDA clears masitinib IND in Amyotrophic Lateral Sclerosis, allowing U.S. patient enrollment to commence in Phase 3 study
31/03/2020 – AB Science today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application, allowing the Company to initiate its masitinib Phase 3 study (AB19001) in amyotrophic lateral sclerosis